NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

Cathie Wood's ARK ETF adjusts portfolio with key stock trades

Published 2024-11-18, 08:08 p/m
ARKK
-
CRSP
-
TWST
-
U
-

Cathie Wood's ARK ETF published their daily trades for Monday, November 18th, 2024, showcasing a series of strategic moves in the biotech and tech sectors. Leading the day's activity was a significant investment in CRISPR Therapeutics AG (NASDAQ:CRSP), where ARK acquired a total of 176,105 shares across its ARKK and ARKG ETFs, amounting to a dollar value of approximately $8.32 million. This latest acquisition follows a trend of bullish behavior on CRISPR Therapeutics by ARK, which has consistently added to its position in the gene-editing company over the past week.

ARK also intensified its stake in Tempus AI Inc (NYSE:TEM), purchasing 86,638 shares through ARKK and ARKG ETFs, totaling around $4.54 million. This move comes right after a substantial buy on Friday, indicating a strong conviction in Tempus AI's potential.

In another major transaction, ARK bought 118,976 shares of Twist Bioscience Corp (NASDAQ:TWST) exclusively through its ARKK ETF, with a total dollar value of nearly $4.39 million. This trade, too, is part of an ongoing accumulation, as ARK had previously bolstered its holdings in Twist Bioscience last week.

On the selling side, ARK executed its largest divestment of the day in Unity Software Inc (NYSE:NYSE:U), offloading a total of 734,972 shares from its ARKK ETF, resulting in proceeds of approximately $12.74 million. This sale continues a pattern of reducing exposure to Unity Software (ETR:SOWGn), which has been observed through several consecutive trading sessions.

Beam Therapeutics Inc (NASDAQ:BEAM) also saw a notable buy from ARK, with 118,324 shares added across ARKK and ARKG ETFs, valued at about $2.85 million. This follows a substantial investment in Beam Therapeutics from the previous trading day, signaling ARK's continued confidence in the genome editing company.

Other transactions included selling shares of Exact Sciences Corp (NASDAQ:EXAS), Standard Biotools Inc (NASDAQ:LAB), and Rocket Lab USA Inc (NASDAQ:RKLB), along with smaller-scale purchases in companies such as Blade Air Mobility Inc (NASDAQ:BLDE), Guardant Health Inc (NASDAQ:GH), and Iridium Communications Inc (NASDAQ:IRDM).

While ARK's daily trades provide a snapshot of the fund's tactical adjustments, the consistent buying or selling patterns in certain stocks offer a glimpse into the longer-term investment strategy that Cathie Wood and her team are employing. Investors and market observers alike will continue to watch ARK's movements closely, as these trades can often signal broader trends and shifts in the innovative sectors that the ETFs target.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.